Impact of Previous Sternotomy on Outcome after Left Ventricular Assist Device Implantation
| Autor: | Jerry Easo, Marcin Szczechowicz, Sabreen Mkalaluh, Juergen Ennker, Konstantin Zhigalov, Harald C. Eichstaedt, Ahmed Mashhour, Maxim Isaev, Bakitbek K. Kadyraliev, Alexander Weymann |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine medicine.medical_specialty Time Factors medicine.medical_treatment 030204 cardiovascular system & hematology Prosthesis Design Ventricular Function Left Prosthesis Implantation 03 medical and health sciences 0302 clinical medicine Risk Factors Clinical endpoint Humans Medicine Adverse effect Aged Retrospective Studies Heart Failure Heartmate ii business.industry Incidence (epidemiology) Recovery of Function Middle Aged Sternotomy Surgery Right Ventricular Assist Device Treatment Outcome 030228 respiratory system Ventricular assist device Propensity score matching Female Heart-Assist Devices Cardiology and Cardiovascular Medicine business Hepatic dysfunction |
| Zdroj: | The Thoracic and Cardiovascular Surgeon. 67:183-190 |
| ISSN: | 1439-1902 0171-6425 |
| Popis: | Background The main purpose of this article is to investigate the impact of previous sternotomy (PS) on the outcome of three different left ventricular assist devices (LVAD). Methods Between June 2007 and February 2018, a total of 121 patients received HeartMate II (60.3%), HeartWare (12.4%), or HeartMate III (27.3%), with or without previous sternotomy (PS and non-PS groups, respectively). Propensity matching resulted in 44 patient pairs. The primary end point was overall survival at 30 days, 1 year, 2, and 5 years, postoperatively. Secondary end points were adverse events. Results The overall cumulative survival rates for the two study groups were significantly different (77, 63, 54, and 38% for non-PS group vs 64, 39, 27, and 24% for PS group, p = 0.036). In the PS group, there was a higher need for intraoperative implantation of short-term right ventricular assist device (22.7 vs 6.8%, p = 0.034) and a higher incidence of hepatic dysfunction (20.5 vs 4.5%, p = 0.025) and acute kidney dysfunction (40.9 vs 20.5%, p = 0.032). Conclusion PS is a reliable predictor of mortality and morbidity after LVAD implantation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|